David Mallery, J.D., MBA is a Co-Founder and President. He is also a co-founder and the President of the International Genomics Consortium (IGC) and Paradigm Diagnostics, and founder of the Molecular Profiling Institute (MPI) and was the President of Caris MPI following the successful acquisition. IGC is instrumental for the biospecimen accrual, amplification, and processing aspects of The Cancer Genome Atlas project for the National Cancer Institute. David launched and helped commercialize many of the top diagnostics in oncology today including Target Now (renamed MI Profile offered through Caris), the Progensa PCA3 prostate screen from Gen-Probe which recently received FDA registration, and Agendia’s MammaPrint. Through Paradigm, a joint-venture with the University of Michigan, Mr. Mallery is also helping launch an evidence driven sequencing based multiplex diagnostic for late stage and difficult to treat solid tumors.
David has a BA in Human Biology and Art from Stanford and a JD/MBA from the University of Colorado, is a life member of the Council on Foreign Relations, and is a member of the Colorado and D.C. Bar Associations.
Scott Morris, PSM is a Co-Founder and Chief Scientific Officer. He oversees innovations, discovery, optimization and software development. He brings a rare combination of skills in biotechnology, industrial engineering, biostatistics and software development. Utilizing these skills, he seamlessly integrates diverse technology and research focuses into focused and efficient objectives. He additionally heads research and development at International Genomics Consortium and Paradigm Diagnostics, and previously headed research and development for the Biospecimen Core Repository (BCR) of the National Cancer Institute’s The Cancer Genome Atlas (TCGA) project.
Scott has filed multiple patents and authored many top-tier publications spanning multiple disciplines. His most successful discoveries include several first-in-class molecular assay developments, an integrated process for rapid discovery/development/deployment of new technologies, highly accurate analysis techniques for complex molecular data, supply chain and process optimization for complex lab processes, specialized datamining techniques for identifying biomarkers, and high-throughput automation of laboratory processes with robotics.
Scott has substantial training in the biological sciences and mathematics, including molecular biology, biotechnology, cell biology, pharmacology, industrial engineering and computational biology and is finishing a PhD in industrial engineering at Arizona State University.
Kyle Hogarth, MD is the Senior Medical Officer. Dr. Hogarth is an expert in pulmonary diseases. At the University of Chicago, he serves as an Assistant Professor of Medicine, the Director of Bronchoscopy and Minimally Invasive Diagnostics, Co-Director of the Upper Aerodigestive Cancer Risk Clinic and the Medical Director of the Pulmonary Rehabilitation Program. He is involved with the minimally invasive diagnosis, management, and staging of lung cancer through bronchoscopy. Dr. Hogarth was one of the first doctors in Illinois to work with the superDimension system -- an electromagnetic navigation system that uses 3-D imaging technology to detect and biopsy lung cancer. He uses endobronchial ultrasound to biopsy lymph nodes, place stents in cancerous airways, and perform all other minimally invasive techniques to help patients with lung cancer. He continues to see patients at least two days a week in clinic.
Dr. Hogarth helped lead the performance of bronchial thermoplasty, a new FDA approved technique to help with asthma. Dr. Hogarth's research also focuses on improving quality of life and outcomes for patients with AAT deficiency and lung cancer. He is an investigator in numerous clinical trials.
Troy Shelton, MS, PMP, is the COO and oversees all aspects of operations, research studies, client services, and logistics. Troy has over 18 years of heath care and project management experience. In addition to his leadership role in Viomics, he is currently the Director of Program Management overseeing the administrative / operational support for the International Genomics Consortium’s (IGC) research programs. He served as the Project Manager for The Cancer Genome Atlas (TCGA) Biospecimen Core Resource (BCR) and oversaw: BCR day to day operations; BCR financial oversight; facilitation of communications. He is also currently overseeing a project for the University of Michigan Biorepository Implementation and is the co-Principle Investigator for the IGC expO Tissues Source Site Network. Prior to joining Viomics and IGC, Troy focused on the delivery of healthcare to the Military and Veteran Affair’s beneficiary population. He oversaw the identification of Web-based self-serve business processes, the development of business plans, the solicitation of Government funding, and the development, testing, implementation and training of new systems. He has several years of leadership experience within a large integrated healthcare delivery system focusing efforts on the development of a compliance-based patient access to outpatient care. His management emphasis on the creation of an operational workflow design and business metrics in order to create synergies between patients, clinicians, and insurance companies, resulted in significant cost savings at military healthcare facilities. Troy was also a Medical Service Officer in the US Army and served as a Healthcare Manager, Company Commander and Executive Officer, along with completing Officer Candidate School and Airborne School.
His degree in Psychology (with an emphasis in Organizational Behavior) from BYU, and his Master’s Degree in Management and Human Resources from Webster University, combined with his years of unique health care experience has assisted him in fostering a proven record of managing complex projects demanding high levels of precision and quality.
Glen Weiss, M.D., is our Clinical Oncology Advisor and is also the Director of Clinical Research and Director of Phase I and II Clinical Trials at the Cancer Treatment Centers of America (CTCA). Dr. Weiss earned a medical degree from Sackler School of Medicine in Tel Aviv, Israel. He then completed an internal medicine residency at SUNY-Downstate in Brooklyn, New York. He went on to finish a hematology/medical oncology fellowship at the University of Colorado Health Sciences Center in Aurora, serving as the Chief Fellow in his final year. Prior to joining CTCA, Dr. Weiss served as the Director, Thoracic Oncology and Associate Clinical Investigator with the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare. Dr. Weiss is also the Chief Medical Officer of the CRAB Clinical Trials Consortium, a position he was elected to in 2011. He earned a Masters in Business Administration from the W.P. Carey School of Business at Arizona State University.
Board certified in internal medicine and medical oncology, Dr. Weiss has already completed numerous clinical trials with investigational agents, a few of which have already gone on to receive FDA approval for certain cancers. He has also received research funding from the American Cancer Society and the International Association for the Study of Lung Cancer, to name a few.
Dr. Weiss has published over 180 peer-reviewed articles and abstracts in journals such as New England Journal of Medicine, Journal of Clinical Oncology, Clinical Cancer Research and Journal of Thoracic Oncology. He has been invited to present at venues around the world, including Seoul, Korea; Orleans, France; Vienna, Austria; and Budapest, Hungary.